[Mitochondrial enzyme ABAD and its role in the development and treatment of Alzheimer's disease].
The amyloid-beta peptide (Abeta) has been associated with Alzheimer's disease (AD) for some time. The original amyloid cascade hypothesis declared that the insoluble extracellular plaques were responsible for main Abeta toxicity. Nowadays, this hypothesis is outdated and soluble intracellular Abeta forms and their effects within the cell have come into the centre of attention. There are many intracellular proteins interacting with Abeta including the mitochondrial enzyme amyloid-binding alcohol dehydrogenase (ABAD). The interaction between ABAD and Abeta impairs mitochondrial functions and ultimately results in cell death. In this review, current findings concerning the enzyme ABAD are summarized. Its role in AD development and its interaction with Abeta as a potential therapeutic target are discussed.